[en] [en] BACKGROUND: While the efficacy of tofacitinib to induce and maintain clinical and endoscopic remission is well established in ulcerative colitis (UC), little is known about its efficacy to induce histological remission.
METHODS: We conducted a retrospective multicentric cohort study. UC patients ≥ 16 years treated by tofacitinib in whom histological activity has been evaluated before and after induction were eligible. The primary endpoint was the histological remission at the end of induction, assessed by the Nancy index and the epithelial neutrophilic infiltrate.
RESULTS: A total of 42 patients with UC (93% previously exposed to an anti-TNF and 81% to vedolizumab) were included between July 2018 and April 2022 and were followed for a median duration of 84 weeks [IQR, 35-134]. At the end of induction period (whether prolonged or not), 19% and 24% of patients achieved histological remission, using the Nancy index and the epithelial neutrophilic infiltrate, respectively. Survival without tofacitinib discontinuation was significantly longer in patients without epithelial neutrophilic infiltrate at the end of induction (whether prolonged or not) compared with patients with epithelial neutrophilic infiltrate (p = 0.036).
CONCLUSION: Tofacitinib induced histological remission in one fifth to one quarter of patients with UC who have previously failed anti-TNF or/and vedolizumab after induction (whether prolonged or not).
Disciplines :
Gastroenterology & hepatology
Author, co-author :
VIEUJEAN, Sophie ; Centre Hospitalier Universitaire de Liège - CHU > > Service de gastroentérologie, hépatologie, onco. digestive
Laharie, David ; CHU de Bordeaux, Centre Medico-chirurgical Magellan, Hôpital Haut-Lévêque, Gastroenterology department, Université de Bordeaux, INSERM CIC 1401, Bordeaux, France
Buisson, Anthony; Université Clermont Auvergne, Inserm, CHU Clermont-Ferrand, 3iHP, Service d'Hépato-Gastro Entérologie, Clermont-Ferrand, France
Roblin, Xavier; Department of Gastroenterology, University Hospital of Saint-Etienne, Saint-Etienne, France
Fumery, Mathurin; Gastroenterology Unit, Amiens University Hospital and PeriTox, Université de Picardie Jules Verne, Amiens UMR-IO1, France
Nancey, Stephane ; Gastroenterology Department CHU Lyon-Sud, Hospices Civils de Lyon, University Claude Bernard Lyon 1, INSERM U1111 - CIRI, Lyon, France
Wils, Pauline; Univ. Lille, Inserm, CHU Lille, U1286 - Institute for Translational Research in Inflammation, Lille F-59000, France
Altwegg, Romain ; Hepato-gastroenterology Department, CHU Montpellier, Montpellier, France
Seidel, Laurence ; Centre Hospitalier Universitaire de Liège - CHU > > Service des informations médico économiques (SIME) ; Biostatistics and medico-economic information department, Liège, Belgium
Caron, Bénédicte; Department of Gastroenterology, Nancy University Hospital, Vandœuvre-lès-Nancy F-54500, France, INSERM, NGERE, University of Lorraine, Nancy F-54000, France, NFINY Institute, Nancy University Hospital, Vandœuvre-lès-Nancy F-54500, France, FHU-CURE, Nancy University Hospital, Vandœuvre-lès-Nancy F-54500, France
Peyrin-Biroulet, Laurent ; Department of Gastroenterology, Nancy University Hospital, Vandœuvre-lès-Nancy F-54500, France, INSERM, NGERE, University of Lorraine, Nancy F-54000, France, NFINY Institute, Nancy University Hospital, Vandœuvre-lès-Nancy F-54500, France, FHU-CURE, Nancy University Hospital, Vandœuvre-lès-Nancy F-54500, France, Groupe Hospitalier privé Ambroise Paré - Hartmann, Paris IBD centre, Neuilly sur Seine 92200, France, Division of Gastroenterology and Hepatology, McGill University Health Centre, Montreal, QC, Canada. Electronic address: peyrinbiroulet@gmail.com
Language :
English
Title :
Histological healing induced by tofacitinib in ulcerative colitis: A multicentre study.
Sandborn, W.J., Su, C., Sands, B.E., D'Haens, G.R., Vermeire, S., Schreiber, S., et al. Tofacitinib as induction and maintenance therapy for ulcerative colitis. N Engl J Med 376:18 (2017), 1723–1736, 10.1056/nejmoa1606910.
Balzola, F., Cullen, G., Ho, G.T., Russell, R.K., Tofacitinib, Wehkamp J., An oral Janus kinase inhibitor, in active ulcerative colitis. N Engl J Med 367:7 (2012), 70–71, 10.1056/NEJMOA1112168.
Colombel, J.F., Osterman, M.T., Thorpe, A.J., Salese, L., Nduaka, C.I., Zhang, H., et al. Maintenance of remission with tofacitinib therapy in patients with ulcerative colitis. Clin Gastroenterol Hepatol, 2020, 10.1016/J.CGH.2020.10.004.
Taxonera, C., Olivares, D., Alba, C., Real-world effectiveness and safety of tofacitinib in patients with ulcerative colitis: systematic review with meta-analysis. Inflamm Bowel Dis 28:1 (2022), 32–40, 10.1093/IBD/IZAB011.
Resál, T., Bacsur, P., Keresztes, C., Bálint, A., Bor, R., Fábián, A., et al. Real-life efficacy of tofacitinib in various situations in ulcerative colitis: a retrospective worldwide multicenter collaborative study. Inflamm Bowel Dis, 2023, 10.1093/ibd/izad135.
Verstockt, B., Volk, V., Jaeckel, C., Dahham, Alsoud, Sabino, João, Nikolaus, S., et al. Longitudinal monitoring of STAT3 phosphorylation and histologic outcome of tofacitinib therapy in patients with ulcerative colitis. Aliment Pharmacol Ther 00 (2022), 1–10, 10.1111/APT.16955.
Buisson, A., Nachury, M., Guilmoteau, T., Altwegg, R., Treton, X., Fumery, M., et al. Real-world comparison of effectiveness between tofacitinib and vedolizumab in patients with ulcerative colitis exposed to at least one anti-TNF agent. Aliment Pharmacol Ther 57:6 (2023), 676–688, 10.1111/apt.17305.
Cohen, N.A., Steinberg, J.M., Silfen, A., Traboulsi, C., Rodriguez, T.G., Singer, J.M., et al. Endo-histologic normalization is achievable with tofacitinib and is associated with improved clinical outcomes. Dig Dis Sci 68:4 (2023), 1464–1472, 10.1007/s10620-022-07716-0.
D'Haens, G., Sandborn, W.J., Feagan, B.G., Geboes, K., Hanauer, S.B., Irvine, E.J., et al. A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology 132:2 (2007), 763–786, 10.1053/J.GASTRO.2006.12.038.
Hanauer, S.B., Kirsner, J.B., Treat the patient or treat the disease?. Dig Dis 30:4 (2012), 400–403, 10.1159/000338139.
Gupta, A., Yu, A., Peyrin-Biroulet, L., Ananthakrishnan, A.N., Treat to target: the role of histologic healing in inflammatory bowel diseases: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 19:9 (2021), 1800–1813, 10.1016/J.CGH.2020.09.046 e4.
Bitton, A., Peppercorn, M.A., Antonioli, D.A., Niles, J.L., Shah, S., Bousvaros, A., et al. Clinical, biological, and histologic parameters as predictors of relapse in ulcerative colitis. Gastroenterology 120:1 (2001), 13–20, 10.1053/gast.2001.20912.
Bessissow, T., Lemmens, B., Ferrante, M., Bisschops, R., Van Steen, K., Geboes, K., et al. Prognostic value of serologic and histologic markers on clinical relapse in ulcerative colitis patients with mucosal healing. Am J Gastroenterol 107:11 (2012), 1684–1692, 10.1038/ajg.2012.301.
Zenlea, T., Yee, E.U., Rosenberg, L., Boyle, M., Nanda, K.S., Wolf, J.L., et al. Histology grade is independently associated with relapse risk in patients with ulcerative colitis in clinical remission: a prospective study. Am J Gastroenterol 111:5 (2016), 685–690, 10.1038/ajg.2016.50.
Bryant, R.V., Burger, D.C., Delo, J., Walsh, A.J., Thomas, S., Von Herbay, A., et al. Beyond endoscopic mucosal healing in UC: histological remission better predicts corticosteroid use and hospitalisation over 6 years of follow-up. Gut 65:3 (2016), 408–414, 10.1136/GUTJNL-2015-309598.
Marchal Bressenot, A., Riddell, R.H., Boulagnon-Rombi, C., Reinisch, W., Danese, S., Schreiber, S., et al. Review article: the histological assessment of disease activity in ulcerative colitis. Aliment Pharmacol Ther, 2015, 957–967, 10.1111/apt.13375.
Geboes, K., Riddell, R., Öst, A., Jensfelt, B., Persson, T., Löfberg, R., A reproducible grading scale for histological assessment of inflammation in ulcerative colitis. Gut 47:3 (2000), 404–409, 10.1136/gut.47.3.404.
Hefti, M.M., Chessin, D.B., Harpaz, N., Steinhagen, R.M., Ullman, T.A., Severity of inflammation as a predictor of colectomy in patients with chronic ulcerative colitis. Dis Colon Rectum 52:2 (2009), 193–197, 10.1007/DCR.0b013e31819ad456.
Gupta, R.B., Harpaz, N., Itzkowitz, S., Hossain, S., Matula, S., Kornbluth, A., et al. Histologic inflammation is a risk factor for progression to colorectal neoplasia in ulcerative colitis: a cohort study. Gastroenterology 133:4 (2007), 1099–1105, 10.1053/j.gastro.2007.08.001.
Rutter, M., Saunders, B., Wilkinson, K., Rumbles, S., Schofield, G., Kamm, M., et al. Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology 126:2 (2004), 451–459, 10.1053/j.gastro.2003.11.010.
Narula, N., Wong, E.C.L., Colombel, J.F., Riddell, R., Marshall, J.K., Reinisch, W., et al. Early change in epithelial neutrophilic infiltrate predicts long-term response to biologics in ulcerative colitis. Clin Gastroenterol Hepatol 20:5 (2022), 1095–1104, 10.1016/j.cgh.2021.07.005 e9.
Estevinho, M.M., Magro, F., Epithelial neutrophilic infiltrate: the rising star in ulcerative colitis. Clin Gastroenterol Hepatol, 2022, e1509–e1510, 10.1016/j.cgh.2021.08.003.
Marchal-Bressenot, A., Salleron, J., Boulagnon-Rombi, C., Bastien, C., Cahn, V., Cadiot, G., et al. Development and validation of the Nancy histological index for UC. Gut 66:1 (2017), 43–49, 10.1136/gutjnl-2015-310187.
Marchal-Bressenot, A., Scherl, A., Salleron, J., Peyrin-Biroulet L. A practical guide to assess the Nancy histological index for UC. Gut, 2016, 1919–1920, 10.1136/gutjnl-2016-312722.
Satsangi, J., Silverberg, M.S., Vermeire, S., Colombel, J.F., The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut, 2006, 749–753, 10.1136/gut.2005.082909.
Battat, R., Duijvestein, M., Guizzetti, L., Choudhary, D., Boland, B.S., Dulai, P.S., et al. Histologic healing rates of medical therapies for ulcerative colitis: a systematic review and meta-analysis of randomized controlled trials. Am J Gastroenterol 114:5 (2019), 733–745, 10.14309/ajg.0000000000000111.
Turner, D., Ricciuto, A., Lewis, A., D'Amico, F., Dhaliwal, J., Griffiths, A.M., et al. STRIDE-II: an update on the selecting therapeutic targets in inflammatory bowel disease (stride) initiative of the international organization for the study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD. Gastroenterology 160:5 (2021), 1570–1583, 10.1053/J.GASTRO.2020.12.031.
Chaparro, M., Garre, A., Mesonero, F., Rodríguez, C., Barreiro-De Acosta, M., Martínez-Cadilla, J., et al. Tofacitinib in ulcerative colitis: real-world evidence from the ENEIDA Registry. J Crohns Colitis 15:1 (2021), 35–42, 10.1093/ECCO-JCC/JJAA145.
Weisshof, R., Aharoni Golan, M., Sossenheimer, P.H., El Jurdi, K., Ollech, J.E., Pekow, J., et al. Real-world experience with tofacitinib in IBD at a tertiary center. Dig Dis Sci 64:7 (2019), 1945–1951, 10.1007/s10620-019-05492-y.
Lair-Mehiri, L., Stefanescu, C., Vaysse, T., Laharie, D., Roblin, X., Rosa, I., et al. Real-world evidence of tofacitinib effectiveness and safety in patients with refractory ulcerative colitis. Dig Liver Dis 52:3 (2020), 268–273, 10.1016/j.dld.2019.10.003.
Hanauer, S., Panaccione, R., Danese, S., Cheifetz, A., Reinisch, W., Higgins, P.D.R., et al. Tofacitinib induction therapy reduces symptoms within 3 days for patients with ulcerative colitis. Clin Gastroenterol Hepatol 17:1 (2019), 139–147, 10.1016/j.cgh.2018.07.009.
Long, M.D., Afzali, A., Fischer, M., Hudesman, D., Abdalla, M., McCabe, R., et al. Tofacitinib response in ulcerative colitis (TOUR): early response after initiation of tofacitinib therapy in a real-world setting. Inflamm Bowel Dis 29:4 (2023), 570–578, 10.1093/ibd/izac121.
Varyani, F., Argyriou, K., Phillips, F., Tsakiridou, E., Moran, G.W., Profile of tofacitinib in the treatment of ulcerative colitis: an evidence-based review of recent data. Drug Des Devel Ther, 2019, 4091–4105, 10.2147/DDDT.S182891.
Rubin, D.T., Dubinsky, M.C., Lukas, M., Quirk, D., Nduaka, C.I., Maller, E., et al. Long-term efficacy of tofacitinib in patients who received extended induction therapy: results of the OCTAVE open study for tofacitinib delayed responders. J Crohn's Colitis 13:Supplement_1 (2019), S050–S052, 10.1093/ecco-jcc/jjy222.077.
Ma, C., Panaccione, R., Xiao, Y., Khandelwal, Y., Murthy, S.K., Wong, E.C.L., et al. REMIT-UC: real-world effectiveness and safety of tofacitinib for moderate-to-severely active ulcerative colitis: a Canadian IBD research consortium multicenter national cohort study. Am J Gastroenterol 118:5 (2023), 861–871, 10.14309/ajg.0000000000002129.
Honap, S., Chee, D., Chapman, T.P., Patel, M., Kent, A.J., Ray, S., et al. Real-world effectiveness of tofacitinib for moderate to severe ulcerative colitis: a multicentre UK experience. J Crohn's Colitis 14:10 (2020), 1385–1393, 10.1093/ecco-jcc/jjaa075.
Sands, B.E., Armuzzi, A., Marshall, J.K., Lindsay, J.O., Sandborn, W.J., Danese, S., et al. Efficacy and safety of tofacitinib dose de-escalation and dose escalation for patients with ulcerative colitis: results from OCTAVE Open. Aliment Pharmacol Ther 51:2 (2020), 271–280, 10.1111/apt.15555.
Biemans, V.B.C., Sleutjes, J.A.M., de Vries, A.C., Bodelier, A.G.L., Dijkstra, G., Oldenburg, B., et al. Tofacitinib for ulcerative colitis: results of the prospective Dutch Initiative on Crohn and Colitis (ICC) registry. Aliment Pharmacol Ther 51:9 (2020), 880–888, 10.1111/apt.15689.
Perin, R.L., Magro, D.O., Andrade, A.R., Argollo, M., Carvalho, N.S., Damião, A.O.M.C., et al. Effectiveness and safety of tofacitinib in the management of ulcerative colitis: a brazilian observational multicentric study. Crohn's Colitis 360 5:1 (2023), 1–7, 10.1093/crocol/otac050.
Deepak, P., Khatiwada, A., Christophi, G.P., Yarur, A.J., Lin, B., Ciorba, M.A., et al. Real-world safety of tofacitinib in inflammatory bowel diseases: a multi-center study. Gastroenterology, 156(6), 2019, S-169, 10.1016/s0016-5085(19)37214-2.
Cremer, A., Lobaton, T., Vieujan, S., Bossuyt, P., Rahier, J.F., Baert, F., et al. Tofacitinib induces clinical and endoscopic remission in biologic refractory ulcerative colitis patients: a real-world Belgian cohort study. J Crohn's Colitis 14:Supplement_1 (2020), S384–S386, 10.1093/ecco-jcc/jjz203.551.
Kolar, M., Lukas, M., Malickova, K., Prochazkova, L., Bortlik, M., Duricova, D., et al. Tofacitinib induction efficiency and intracellular cytokine dynamics in ulcerative colitis: results from clinical practice. J Crohn's Colitis, 14(Supplement_1), 2020, S348, 10.1093/ecco-jcc/jjz203.497.
Rutka, M., Farkas, K., Pigniczki, D., Szántó, K., Anita, B., Bor, R., et al. Efficacy of tofacitinib in patients with ulcerative colitis after previous ineffective biological therapies. J Crohn's Colitis 14:Supplement_1 (2020), S545–S546, 10.1093/ecco-jcc/jjz203.791.
Watanabe, K., Kawai, M., Koshiba, R., Fujimoto, K., Kojima, K., Kaku, K., et al. Efficacy including rapid response and safety of tofacitinib in Japanese patients with ulcerative colitis: a preliminary investigation in a specialised IBD centre. J Crohn's Colitis, 14(Supplement_1), 2020, S535, 10.1093/ecco-jcc/jjz203.776.
Xiao, Y., Lakatos, P.L., Bourdages, R., et al. Efficacy of tofacitinib for the treatment of moderate-to-severe ulcerative colitis: real-world data. J Crohn's Colitis 14 (2020), S444–S445, 10.1093/jcag/gwz047.231.
Yoshimura N., Okano S., Sako M. et al. Efficacy and safety of tofacitinib in patients with moderate-to-severe ulcerative colitis: a real-world retrospective study. J Crohn's Colitis. Available at: https://www.worldcat.org/fr/search?q=ti:Efficacyandsafetyoftofacitinibinpatientswithmoderate-to-severeulcerativecolitis%3Aareal-worldretrospectivestudy&qt=advanced&dblist=638. Accessed August 5, 2023.
Shimizu, H., Fujii, T., Hibiya, S., Motobayashi, M., Suzuki, K., Takenaka, K., et al. Rapid prediction of 1-year efficacy of tofacitinib for treating refractory ulcerative colitis. Intest Res 19:1 (2021), 115–118, 10.5217/IR.2020.00030.
Alatab, S., Vahedi, H., Sadeghi, A., Sima, A., Dinari, Z., Induction therapy with tofacitinib in patients with moderate-to-severe ulcerative colitis. Turkish J Gastroenterol, 30(Supplement 3), 2019, S149.
Reinisch, W., Reinink, A.R., Higgins, P.D.R., Factors associated with poor outcomes in adults with newly diagnosed ulcerative colitis. Clin Gastroenterol Hepatol 13:4 (2015), 635–642, 10.1016/j.cgh.2014.03.037.
Shah, S.C., Colombel, J.F., Sands, B.E., Narula, N., Systematic review with meta-analysis: mucosal healing is associated with improved long-term outcomes in Crohn's disease. Aliment Pharmacol Ther, 2016, 317–333, 10.1111/apt.13475.
Lasa, J.S., Olivera, P.A., Danese, S., Peyrin-Biroulet, L., Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis. Lancet Gastroenterol Hepatol 7:2 (2022), 161–170, 10.1016/S2468-1253(21)00377-0.
